Transurethral microwave thermotherapy: the gold standard for minimally invasive therapies for patients with benign prostatic hyperplasia?
From all available minimally invasive methods for the treatment of symptomatic benign prostatic hyperplasia (BPH), transurethral microwave thermotherapy (TUMT) has gained a firm position as the most attractive option. Recent research has produced innovations in high-energy TUMT, including new treatment protocols, refined selection criteria, and monitoring of intraprostatic temperature. Furthermore, long-term results from randomized studies comparing TUMT with transurethral resection of the prostate (TURP) or medical treatment are now available. All these data indicate that more durable clinical outcomes and less morbidity can be achieved with TUMT, strengthening its position as a standard treatment for BPH. This paper describes the status of TUMT in the treatment of lower urinary tract symptoms related to BPH, focusing on variations in the outcomes with different devices, the durability of treatment outcomes, morbidity, selection criteria, and cost. The relation of TUMT to medical management and TURP also is addressed.
de la Rosette
Jean J M C H
JJ
Department of Urology, University Medical Center St. Radboud, Nijmegen, The Netherlands. j.j.delarosette@amc.uva.nl
Laguna
M Pilar
MP
Gravas
Stavros
S
de Wildt
Michel J A M
MJ
D003362:Cost-Benefit Analysis; D003972:Diathermy / Q000191:economics / Q000379:methods*; D006801:Humans; D008297:Male; D008872:Microwaves / Q000627:therapeutic use*; D009017:Morbidity; D018579:Patient Selection; D011470:Prostatic Hyperplasia / Q000191:economics / Q000453:epidemiology* / Q000628:therapy*; D016896:Treatment Outcome